Our Vision
Innovation
Translating novel biological insights into long-term transformative treatments
Evidence Driven
Drug discovery and development that are built on a deep understanding of central fibrotic mediators and pathways
Improving Lives
Committed to improve the quality of life of patients suffering from seriously debilitating and life-threatening diseases
Our Focus
Chemomab Therapeutics is a clinical-stage biotech company discovering and developing innovative therapeutics for rare fibro-inflammatory diseases with high unmet need
Innovation & Discovery
Chemomab discovered the key role of the soluble chemokine CCL24 in promoting liver, skin and lung fibrosis.
The Challenge
Fibrosis-related diseases are a significant unmet need that dramatically affect patients health and quality of life.
Damaged tissue repairs itself through a sequence of controlled inflammatory and fibrotic processes. However, uncontrolled healing processes can create a vicious cycle of inflammation and fibrosis – an excessive, sustained, chronic inflammatory response that activates fibroblasts, and replaces functional tissue with fibrous scar tissue.
CCL24 – a Key Player
Regulating CCL24 is key to halting fibrosis-related conditions
Chemomab discovered that the soluble chemokine CCL24 plays a key role in promoting inflammation and fibrosis via a dual pathway. CCL24 promotes both the recruitment of immune cells to the damaged tissue and supports its polarization to create a pro-fibrotic environment. In parallel, CCL24 directly activates tissue fibroblasts, enhances their transition into myofibroblasts and induces the uncontrolled production of extracellular matrix.
CM-101 Therapeutic Platform
Pioneering innovation to treat fibrosis-related diseases.
Chemomab’s lead compound, CM-101, currently tested in phase II clinical studies, is a first-in-class humanized monoclonal antibody designed to bind to and block CCL24 activity.
CM-101 interferes with the main pathologies that promote fibrosis and inflammation. It is highly effective in ameliorating fibrosis, as shown across multiple in vivo, in vitro and ex vivo studies, including experimental models of liver, skin and lung fibrosis. CM-101 is currently under clinical development for Primary Sclerosing Cholangitis , Systemic Sclerosis and Non-Alcoholic Steatohepatitis.
Product Pipeline CM-101
Addressing fibro-inflammatory diseases with high unmet need
Indication
Indication
Indication
Target
Target
Target
Discovery
Discovery
Discovery
Preclinical
Preclinical
Preclinical
Phase 1
Phase 1
Phase 1
Phase 2
Phase 2
Phase 2
Phase 3
Phase 3
Phase 3
Liver Fibrosis Biomarkers & Subcutaneous Formulation
Liver Fibrosis Biomarkers & Subcutaneous Formulation
Liver Fibrosis Biomarkers & Subcutaneous Formulation
CCL24
CCL24
CCL24
Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis
CCL24
CCL24
CCL24
Systemic Sclerosis
Systemic Sclerosis
Systemic Sclerosis
CCL24
CCL24
CCL24
Fibro-inflammatory Diseases
Fibro-inflammatory Diseases
Fibro-inflammatory Diseases
CCL24
CCL24
CCL24
Next-Gen (Novel Targets)
Indication
Indication
Indication
Target
Target
Target
Discovery
Discovery
Discovery
Preclinical
Preclinical
Preclinical
Phase 1
Phase 1
Phase 1
Phase 2
Phase 2
Phase 2
Phase 3
Phase 3
Phase 3
TBD
TBD
TBD
Screening
Screening
Screening